USPTO serial 98507838
ELSA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SMITH, LAURA E
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ELSA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Princeton, NJ, US
Princeton, NJ, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Perry Gattegno
Perry Gattegno Litwin Kach LLP401 N Michigan Ave, Suite 1200Chicago, IL 60611United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of central nervous system diseases, neuromuscular diseases, metabolic diseases, and diseases related to RNA processing and translation | ACTIVE | — |
| 042 | Biochemical research and development, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Biotechnology research, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Gene therapy research, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Pharmaceutical drug development services, namely, development and design of anti-sense oligonucleotides; Pharmaceutical products development, namely, development and design of anti-sense oligonucleotides; Pharmaceutical research and development, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of RNA-targeted drugs, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of nucleic acids, biologics, central nervous system diseases, metabolic diseases, and small molecule drugs, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of gene therapy, namely, using bioinformatics to develop knowledge of the RNA transcript splicing regulation machinery to improve efficacy; Research and development in the pharmaceutical and biotechnology fields, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines, namely, development and design of anti-sense oligonucleotides; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy, namely, development and design of anti-sense oligonucleotides | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 30, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 30, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 26, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 1, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 1, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 25, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 30, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 14, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 14, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 14, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 9, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 9, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 9, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 18, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 18, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 18, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 27, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jan 27, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Nov 6, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 6, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 6, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 1, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 6, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 18, 2024 | NWAP | NEW APPLICATION ENTERED | — |